-
MindMed Appoints Dr. Robert Dworkin to Scientific Advisory Board
americanpharmaceuticalreview
August 11, 2021
MindMed, a biotech company developing psychedelic-inspired therapies, announced the addition of Robert H. Dworkin, Ph.D. to its Scientific Advisory Board. Dr. Dworkin has spent over 35 years conducting clinical research on pain.
-
MindMed Joins Digital Medicine Society to Improve Health With Technology
americanpharmaceuticalreview
August 04, 2021
MindMed, a biotech company developing psychedelic-inspired therapies, announced that it will participate in and financially support the Digital Medicine Society's (DiMe) Digital Health Measurement Collaborative Community (DATAcc), an effort to develop ...
-
MindMed Announces Partnership with Datavant, a Leading Health Data Connectivity Company
firstwordpharma
July 09, 2021
MindMed and Datavant announced a partnership through which MindMed will use Datavant's privacy-protecting technology to link MindMed's clinical trial data to external data from both clinical and real-world sources.
-
MindMed Initiates Dosing in Human Safety Study of Opioid Addiction Treatment
americanpharmaceuticalreview
April 20, 2020
Mind Medicine has begun dosing the first subject in an additional Phase 1 human safety trial of 18-MC. The safety trial has commenced on time and as scheduled, even during the COVID-19 pandemic.
-
MindMed Advances Potential Treatment for Opioid Addiction
americanpharmaceuticalreview
March 30, 2020
Mind Medicine announced the company has begun enrollment in further human safety studies of 18-MC, the company's orally-active drug candidate for the treatment of opioid use disorders.